|155.35||-6.18||-3.83%||Vol 551.09K||1Y Perf -30.70%|
|Sep 24th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||231.20||Analyst Rating||Moderate Buy 1.75|
|Potential %||48.83||Finscreener Ranking||★★+ 48.31|
|Insiders Trans % 3/6/12 mo.||-100/-100/-97||Value Ranking||★★+ 48.38|
|Insiders Value % 3/6/12 mo.||-100/-100/-90||Growth Ranking||★★★★+ 64.62|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-90||Income Ranking||— -|
|Price Range Ratio 52W %||0.49||Earnings Rating||Strong Sell|
|Market Cap||5.07B||Earnings Date||27th Oct 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|10 Years||1 026.54%|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||27th Oct 2021|
|Estimated EPS Next Report||1.35|
|EPS Growth Next 5 Years %||11.00|
|Avg. Weekly Volume||310.00K|
|Avg. Monthly Volume||336.94K|
|Avg. Quarterly Volume||335.80K|
Amedisys Inc (NASDAQ: AMED) stock closed at 155.35 per share at the end of the most recent trading day (a -3.83% change compared to the prior day closing price) with a volume of 551.09K shares and market capitalization of 5.07B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Healthcare Providers & Services industry, Healthcare sector and employs 21000 people. Amedisys Inc CEO is Paul B. Kusserow.
The one-year performance of Amedisys Inc stock is -30.7%, while year-to-date (YTD) performance is -47.04%. AMED stock has a five-year performance of 218.86%. Its 52-week range is between 154.52 and 325.12, which gives AMED stock a 52-week price range ratio of 0.49%
Amedisys Inc currently has a PE ratio of 23.00, a price-to-book (PB) ratio of 6.39, a price-to-sale (PS) ratio of 2.49, a price to cashflow ratio of 21.00, a PEG ratio of 2.32, a ROA of 14.82%, a ROC of 21.45% and a ROE of 30.23%. The company’s profit margin is 11.42%, its EBITDA margin is 17.40%, and its revenue ttm is $2.20 Billion , which makes it $67.30 revenue per share.
Of the last four earnings reports from Amedisys Inc, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $1.35 for the next earnings report. Amedisys Inc’s next earnings report date is 27th Oct 2021.
The consensus rating of Wall Street analysts for Amedisys Inc is Moderate Buy (1.75), with a target price of $231.2, which is +48.83% compared to the current price. The earnings rating for Amedisys Inc stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Amedisys Inc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Amedisys Inc has a Sell technical analysis rating based on Technical Indicators (ADX : 20.37, ATR14 : 6.12, CCI20 : -167.53, Chaikin Money Flow : -0.18, MACD : -10.15, Money Flow Index : 21.79, ROC : -16.06, RSI : 23.35, STOCH (14,3) : 2.52, STOCH RSI : 0.00, UO : 30.59, Williams %R : -97.48), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Amedisys Inc in the last 12-months were: Bruce D. Perkins (Buy at a value of $259 376), Christopher Gerard (Option Excercise at a value of $0), Christopher Gerard (Sold 9 350 shares of value $2 461 683 ), David Kemmerly (Option Excercise at a value of $0), David Kemmerly (Sold 1 003 shares of value $275 810 ), Denise M. Bohnert (Option Excercise at a value of $24 380), Denise M. Bohnert (Sold 1 176 shares of value $356 921 ), Michael North (Option Excercise at a value of $0), Paul B. Kusserow (Option Excercise at a value of $0), Scott G. Ginn (Option Excercise at a value of $213 330), Scott G. Ginn (Sold 7 800 shares of value $2 027 074 ), Sharon Brunecz (Option Excercise at a value of $0)
Fri, 06 Aug 2021 12:34 GMT Amedisys (AMED) Receives a Buy from Jefferies- TipRanks. All rights reserved.
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.